###### 

Table 1.

  Arguments of committee                                                                                                       Comment                                                                                                                          Reference
  ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------
  ART reduces 96% of transmissions                                                                                             Absolute reduction 0.9 to 0.1 in 100 person years 82% of transmissions in Africa, and 73% of the linked transmissions in o       \[[@CIT0001_19766]\]
  Increase of 38% of AIDS events, if started \<350 \<500 CD4 cells                                                             Absolute increase of AIDS events from 1.78 to 3.63% for a time period of five years, no reduction in mortality                   \[[@CIT0002_19766]\]
  ART implementation \<500 CD4 cell/uL associated with slower disease progression                                              Absolute decrease of AIDS Events from 1.17 to 0.98/100 person years,                                                             \[[@CIT0003_19766]\]
  Higher CD4 cell count associated with decreased risk of AIDS and death in viral suppressed patients up to 500 CD4 cells      Absolute increase of AIDS event or death increase from 0.79 to 1.2 per 100 py                                                    \[[@CIT0004_19766]\]
  Lower CD4 nadir leads to poor recovery and increased morbidity and mortality                                                 Only patients with CD4-Nadir \<200/uL were included                                                                              \[[@CIT0005_19766]\]
  41% reduction of serious WHO stage 4 events, pulm. tuberculosis bacterial infection and death treated vs non-treated early   Absolute increase from 2.4 to 3.96/100 py early vs non-early treated                                                             \[[@CIT0001_19766]\]
  Patients with CD4 cells \>500 has an identical risk of cancer compared to non-HIV                                            Only comparison 200-499 and \>500 CD4 cells, no data on patients 350-499 CD4 cells                                               \[[@CIT0006_19766]\]
  Cross-section studies suggest a benefit of early ART on cardiovascular risk                                                  Only arterial flow mediated dilatation measured. Only comparison between \<350 and \>350 CD4 cells.                              \[[@CIT0007_19766],[@CIT0008_19766]\]
  Renal disease increased at lower CD4 counts                                                                                  Risk of renal disease increases only if CD4 cells fall below 200 cell/uL                                                         \[[@CIT0009_19766]\]
  Communities with high ART use have lower rates of new infections                                                             Significant overall, but not if only data from 2004 to 2009 are analyzed, with an increase of ART of 50%. Overall significance   \[[@CIT0010_19766]\]
  Decreasing "community viral load" accompanied by decreasing incidence of new HIV infection                                   No comment                                                                                                                       \[[@CIT0011_19766]\]
